Glaucoma (Primary Open-Angle): Screening

1. Trials that include larger numbers of Black and Hispanic/Latino persons reporting on the effects of screening and treatment of POAG.
2. Screening trials that assess referral to an eye care specialist and use contemporary screening and diagnostic modalities (e.g., spectral-domain optical coherence tomography [OCT] or swept-source OCT), are of sufficient duration, and include vision-related outcomes (visual impairment, vision-related function, quality of life, and other patient-reported outcomes).
3. Research on the accuracy of risk assessment tools both for early identification of persons at increased risk of glaucoma and to inform screening strategies.
4. Research to better understand the long-term effects of treatment on visual impairment, vision-related function, and quality of life and to verify that benefits of treatment are retained in persons diagnosed with POAG using newer imaging methods such as OCT.

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary open-angle glaucoma (PAOG) in asymptomatic adults 40 years or older.

Glaucoma (Primary Open-Angle): Screening Read full statement 1